The Russian cancer vaccine is ready for use, Izvestia reported, citing Veronika Skvortsova, head of the Federal Medical-Biological Agency.
Preclinical studies have confirmed the safety and efficacy of the drug. At the end of the summer, the FMBA sent documents to the Ministry of Health to obtain permission for clinical use.
As previously reported, from September 2025, the vaccine will be used to treat patients with primary melanoma, as well as those who have undergone certain stages of therapy. The drug was developed by the Gamaleya Research Center for Epidemiology and Microbiology.
Read materials on the topic:
Russian cancer vaccine has successfully passed preclinical trials
Now on home
The reason for indexation may be inflation, an increase in VAT, and rising production costs
The Ministry of Industry and Trade believes that the increase in the levy will not affect responsible manufacturers
The crew accelerated the aircraft to 580 km/h instead of the cruising speed of 450 km/h
Ship equipment comes to Russia from China at inflated prices
Almaz-Antey and the Belarusian Ministry of Defense signed a contract for equipment maintenance
The complex's computing resources allow for the competent distribution of targets between launchers
Among the spacecraft are Aist-2T No. 1 and No. 2
Deputy Prime Minister Novak announced a postponement of the deadlines, but confirmed the commitment to developing the sector
Design engineers without experience are promised salaries from 80 thousand rubles
Hard and dense shot ensures the destruction of the target from the first hit, regardless of the drone's body material
Almost all body elements are zinc-treated
SOGAZ lost the case in court against UEC-UMPO